1 / 28

Anticoagulation for PCRRT

Anticoagulation for PCRRT. Dr. Peter Skippen, PICU. BC Children’s Hospital, Vancouver. CANADA. Outline. Normal Coagulation Anticoagulation: Options Heparin Citrate Others Conclusions. Ca ++. Ca ++. Ca ++. Ca ++. Ca ++. Ca ++. Mechanisms of Filter Thrombosis.

hwarman
Télécharger la présentation

Anticoagulation for PCRRT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Anticoagulation for PCRRT Dr. Peter Skippen, PICU. BC Children’s Hospital, Vancouver. CANADA.

  2. Outline • Normal Coagulation • Anticoagulation: Options • Heparin • Citrate • Others • Conclusions

  3. Ca++ Ca++ Ca++ Ca++ Ca++ Ca++ Mechanisms of Filter Thrombosis TISSUE FACTOR TF:VIIa CONTACT PHASE XII activation XI IX monocytes / platelets / macrophages X Va VIIIa Ca++ platelets Xa Phospholipid surface prothrombin THROMBIN NATURAL ANTICOAGULANTS (APC, ATIII) FIBRINOLYSIS ACTIVATION FIBRINOLYSIS INHIBITION fibrinogen CLOT

  4. Coagulation in Critically Ill Child • Pre-existing inflammatory states • sepsis • trauma • shock • hypercoagulable / thrombohemorrhagic states • Organ failure states • liver / renal (2˚ coagulation abnormalities) • blood oncology / marrow failure • Perioperative • cardiopulmonary bypass • Medications • platelet effects • immunosuppressive / oncologic • thrombogenic / fibrinolytic

  5. Factors Affecting Filter Life • Pre-existing condition of patient’s coag /anticoag system • Treatment characteristics • A-V vs. V-V • vascular access • diffusion vs. convection • filtration fraction • blood flow • membrane material and geometry • circuit alarms

  6. Sites of Thrombus Formation • any blood surface interface • hemofilter • bubble trap • catheter • areas of turbulence / resistance • very high blood flow rates • luer lock connections / 3 way stopcocks

  7. Technical aspects cannulae cannulation site circuitry blood flow rate FF predilution? No anticoagulation Saline flush? Hemodilution? Heparin unfractionated LMWH Citrate Others prostacyclin danaparoid hirudin nafamostate mesylate Anticoagulation: Options

  8. Unfractionated Heparin

  9. Ca++ Ca++ Ca++ Ca++ Ca++ Ca++ Sites of Action of Heparin LMWH TISSUE FACTOR TF:VIIa CONTACT PHASE XII activation XI IX monocytesplatelets macrophages X Va VIIIa Ca++ platelets Xa Phospholipid surface ATIII prothrombin UF HEPARIN THROMBIN NATURAL ANTICOAGULANTS (APC, ATIII) FIBRINOLYSIS ACTIVATION FIBRINOLYSIS INHIBITION fibrinogen CLOT

  10. Heparin - Problems • bleeding • unable to inhibit thrombin bound to clot • unable to inhibit Xa bound to clot • ongoing thrombin generation • direct activation of platelets • thrombocytopenia • extrinsic pathway unaffected

  11. No Heparin Systemically Heparinized NO surface - heparinized NO surface - no heparin Compliments of Dr. Gail Annich, University of Michigan

  12. Unfractionated Heparin Hoffbauer R et al. Kidney Int. 1999;56:1578-1583.

  13. LMWH: Theoretic Advantages • Reduced risk of bleeding • Less risk of HIT

  14. LMWH Hoffbauer R et al. Kidney Int. 1999;56:1578-1583.

  15. LMWH • no difference in filter life • no difference in risk of bleeding • no quick antidote • need to monitor levels • risk of accumulation • renal clearance • minimal filter clearance • increased cost

  16. Citrate

  17. Citrate: Mechanism of Action • Binds calcium - essential coagulation co-factor

  18. Citrate: Clinical Data

  19. Ca++ Ca++ Ca++ Ca++ Ca++ Ca++ Sites of Action of Citrate TISSUE FACTOR TF:VIIa CONTACT PHASE XII activation XI IX monocytes / platelets / macrophages X Va VIIIa Ca++ platelets Xa Phospholipid surface prothrombin CITRATE THROMBIN NATURAL ANTICOAGULANTS (APC, ATIII) FIBRINOLYSIS ACTIVATION FIBRINOLYSIS INHIBITION fibrinogen CLOT

  20. Citrate: Advantages • No need for heparin • Less bleeding risk • Simple to monitor

  21. Citrate Hoffbauer R et al. Kidney Int. 1999;56:1578-1583.

  22. Citrate: Technical Considerations • ensure catheter patency • establish desired blood flow • pre-filter infusion • initial citrate flow = x 2 (mls/hr) BFR (mls/min) • systemic calcium infusion • aim for pre-filter ionized Ca++ < 0.4mmol/L • adjust dialysate as needed • anticipate alkalosis • adjust electrolyte replacements as necessary • Na+ / PO4-- / Ca++ / Mg++

  23. Citrate: Problems • metabolic alkalosis • metabolized in liver / skeletal muscle / other tissues • electrolyte disorders • hypernatremia • hypocalcemia • hypomagnesemia • sugar load • “citrate lock”? • hepatic failure • ?cardiac toxicity • neonatal hearts

  24. Citrate: Clinical Data

  25. Citrate: Caution? • Congenital metabolic diseases? • ? mitochondropathies • Severe liver disease / hepatic failure • Excessive calcium requirements • Massive blood transfusions

  26. Hirudin • Highly selective / specific thrombin inhibitor • Minimal non-renal clearance • Long acting • No specific antagonist

  27. Nafamostate Mesylate • Synthetic protease inhibitor • Inhibits thrombin, Xa, XIIa, TF-VIIa complex • Low MW  high EC clearance • ACT for monitoring • No antidote but short half life

  28. Conclusions • Wide range of practice • UF heparin most commonly used anticoagulant • Citrate may be agent of choice in most situations?

More Related